178 results on '"Sumanasuriya, Semini"'
Search Results
2. Applications of liquid biopsies in metastatic castration resistant prostate cancer
3. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
4. CD38 in Advanced Prostate Cancers
5. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
6. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
7. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
8. Hypoxia and Noncoding RNAs in Taxane Resistance
9. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
10. Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
11. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
12. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids
13. Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
14. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
15. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
16. Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
17. Figure S1 from HER3 Is an Actionable Target in Advanced Prostate Cancer
18. Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
19. Data from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
20. Supplementary Figure S2 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
21. Supplemental Table S1 from Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
22. Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
23. Supplementary Figure 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
24. Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
25. Supplementary Figure 3 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
26. Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
27. Supplementary Table 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
28. Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
29. Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
30. Supplementary Legends from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
31. Legends supplementary figures/ tables from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
32. Supplementary Methods from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
33. Data from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
34. Figure Legends from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
35. Supplementary Figures from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
36. Supplementary Tables from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
37. Abstract 3415: The neutrophil-to-lymphocyte ratio (NLR) reflects intratumor myeloid derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancers (mCRPC)
38. The molecular underpinnings of prostate cancer: impacts on management and pathology practice
39. HER3 Is an Actionable Target in Advanced Prostate Cancer
40. CD38 in Advanced Prostate Cancers
41. Abstract PO003: CD38 in the advanced prostate cancer
42. Abstract LB-270: Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data
43. Genomics of lethal prostate cancer at diagnosis and castration resistance
44. PSMA heterogeneity and DNA repair defects in prostate cancer.
45. Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.
46. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
47. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
48. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
49. Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
50. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.